Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bristol-Myers, Isis Form Antisense Pact
May 14, 2007
| A version of this story appeared in
Volume 85, Issue 20
Bristol-Myers Squibb and Isis Pharmaceuticals have formed a collaboration to develop antisense drugs targeting proprotein convertase subtilisin kexin 9 for the prevention of cardiovascular disease. BMS will pay Isis a $15 million up-front licensing fee, at least $9 million in research funding, and up to $168 million more if certain milestones are reached. The two firms also will work together to identify additional drugs "with advanced antisense chemistries."
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter